Overview

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Status:
Recruiting

Trial end date:
2027-09-23

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Mirikizumab